Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IOM on cancer trials

This article was originally published in The Gray Sheet

Executive Summary

The National Cancer Institute should coordinate with FDA on the review and oversight of new device and drug trials "to eliminate iterative review steps" and FDA should follow through on plans to establish a coordinated cancer program to avoid conflicting review requirements for cancer combination products, the Institute of Medicine recommends in its April 15 1report on the U.S. cancer clinical trial system. IOM also urges enhanced use of biomarkers in clinical trial protocols. The report was developed at the request of NCI to outline an approach to reforming the cancer clinical trials infrastructure. It includes four broad-based recommendations: to improve the speed and efficiency of the design, launch and conduct of trials; to better incorporate innovative science into trials; to improve the process for prioritizing and funding trials; and to increase patient and physician participation
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT028760

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel